MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The companys product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
